• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Surmodics Inc.

    5/13/25 4:44:21 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care
    Get the next $SRDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    SURMODICS INC

    (Name of Issuer)


    COMMON-STOCK

    (Title of Class of Securities)


    868873100

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    868873100


    1Names of Reporting Persons

    Barclays PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    7Sole Dispositive Power

    8Shared Dispositive Power

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12Type of Reporting Person (See Instructions)



    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SURMODICS INC
    (b)Address of issuer's principal executive offices:

    9924 West 74th Street
    Item 2. 
    (a)Name of person filing:

    Barclays PLC
    (b)Address or principal business office or, if none, residence:

    1 Churchill Place, London - E14 5HP
    (c)Citizenship:

    X0
    (d)Title of class of securities:

    COMMON-STOCK
    (e)CUSIP No.:

    868873100
    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Barclays PLC
     
    Signature:Ramya Rao
    Name/Title:Director
    Date:05/13/2025
    Get the next $SRDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRDX

    DatePrice TargetRatingAnalyst
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    3/7/2025$43.00Hold → Buy
    Lake Street
    6/13/2023$36.00Hold → Buy
    Needham
    2/13/2023Buy → Hold
    Needham
    2/4/2022$70.00 → $58.00Buy
    Needham
    11/10/2021$76.00 → $70.00Buy
    Needham
    9/8/2021$68.00 → $76.00Buy
    Needham
    More analyst ratings

    $SRDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Surmodics downgraded by Barrington Research

    Barrington Research downgraded Surmodics from Mkt Perform to Underperform

    11/14/25 11:19:52 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Lake Street with a new price target

    Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

    3/7/25 8:21:43 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics upgraded by Needham with a new price target

    Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

    6/13/23 7:48:05 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    SEC Filings

    View All

    SEC Form 8-K filed by Surmodics Inc.

    8-K - SURMODICS INC (0000924717) (Filer)

    11/12/25 6:15:33 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Surmodics Inc.

    10-Q - SURMODICS INC (0000924717) (Filer)

    8/8/25 7:55:24 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SURMODICS INC (0000924717) (Filer)

    8/8/25 7:00:09 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

    Surmodics, Inc. (NASDAQ:SRDX) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the "District Court") has denied a request by the U.S. Federal Trade Commission (the "FTC") and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC ("GTCR") from consummating the proposed acquisition of the Company by an affiliate of GTCR (the "Merger"). Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to

    11/10/25 7:00:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

    Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL natio

    11/4/25 6:15:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3

    PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with symptomatic infrainguinal vessels will be shared. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extremity (infrainguinal) vessels treated with the Pounce™ Thrombectomy Platform. The presentati

    11/3/25 6:15:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heine Lisa Wipperman covered exercise/tax liability with 2,115 shares and exercised 2,640 shares at a strike of $27.30, increasing direct ownership by 4% to 13,978 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/20/25 4:12:56 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Director Dantzker David exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,216 shares, increasing direct ownership by 3% to 40,183 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/18/25 5:22:54 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Director Bedoya Jose H exercised 5,275 shares at a strike of $27.30 and covered exercise/tax liability with 4,224 shares, increasing direct ownership by 4% to 30,008 units (SEC Form 4)

    4 - SURMODICS INC (0000924717) (Issuer)

    2/18/25 5:20:51 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Financials

    Live finance-specific insights

    View All

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call to discuss the third quarter of fiscal 2025 financial results and accomplishments. About Surmodics, Inc. Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also

    8/6/25 4:05:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million, a decrease of 12% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $27.8 million, a decrease of 10% year-over-year GAAP loss of $(5.2) million, compared to net income of $0.2 million in the prior-year period Adjusted EBITDA(2) of $1.9 million, compared to $4.8 mil

    4/30/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/6/24 1:30:21 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    10/23/24 10:43:41 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $SRDX
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

    6/27/23 7:05:00 AM ET
    $KRMD
    $SRDX
    Medical/Dental Instruments
    Health Care